BridgeBio Pharma (BBIO) Equity Average (2018 - 2026)

BridgeBio Pharma has disclosed Equity Average across 9 years of filings, most recently posting -$2.2 billion for Q1 2026.

• Equity Average for Q1 2026 came in at -$2.2 billion, down 40.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 40.64% YoY), and the FY2025 annual result was -$1.8 billion, down 26.55% from the prior year.
• Equity Average came in at -$2.2 billion for Q1 2026 at BridgeBio Pharma, down from -$2.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$954.0 million in Q1 2022 to a low of -$2.2 billion in Q1 2026.
• The 5-year median for Equity Average is -$1.3 billion (2023), against an average of -$1.4 billion.
• Across the five-year window, Equity Average tumbled 573.95% in 2022 and climbed 17.33% in 2024, its largest moves.
• BridgeBio Pharma's Equity Average stood at -$1.2 billion in 2022, then fell by 7.04% to -$1.3 billion in 2023, then decreased by 5.46% to -$1.3 billion in 2024, then slumped by 50.17% to -$2.0 billion in 2025, then slipped by 8.33% to -$2.2 billion in 2026.
• The last three Equity Average figures came in at -$2.2 billion (Q1 2026), -$2.0 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.